Ken Griffin Purple Biotech Ltd. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Purple Biotech Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 6,600 shares of PPBT stock, worth $5,346. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,600
Previous 6,300
4.76%
Holding current value
$5,346
Previous $4,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PPBT
# of Institutions
23Shares Held
2.64MCall Options Held
6.6KPut Options Held
0-
Armistice Capital, LLC New York, NY2.12MShares$1.71 Million0.02% of portfolio
-
Kingswood Wealth Advisors, LLC San Diego, CA186KShares$150,7410.01% of portfolio
-
Morgan Stanley New York, NY137KShares$110,6540.0% of portfolio
-
Xtx Topco LTD London, X029.1KShares$23,5700.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny21.4KShares$17,3640.0% of portfolio
About PURPLE BIOTECH LTD.
- Ticker PPBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,303,300
- Market Cap $14.8M
- Description
- Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...